|
(PRNewswire) -- DuPont (NYSE: DD)
and Royal DSM N.V. announce an agreement to form a joint venture to develop,
manufacture and commercialize advanced surgical biomedical materials, pending
European Union regulatory approval. The joint venture will be named Actamax
Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will
each share a 50 percent interest.
The joint venture will address the market for surgical sealants, adhesion
barriers and tissue adhesives – a large and underserved market of more than 100
million annual surgical procedures worldwide. The outcome of many surgical
procedures could be positively impacted using next-generation materials under
development by the joint venture.
Actamax Surgical Materials LLC will build a comprehensive biomedical
product portfolio based on several patent-protected biodegradable hydrogel
technologies. The early technology development was completed using DuPont
materials science and biotechnology capabilities. Commercialization will
rely on the medical polymer processing and manufacturing capabilities of
DSM.
mrcplast.com |
